Human Otic Progenitor Isolation Using Cell Surface Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating human otic progenitor cells from mixed populations are inefficient, and no specific cell-surface markers have been identified for human otic progenitors, limiting their isolation and application in therapeutic strategies.
Innovation Solution
The use of at least two cell surface markers selected from SSEA1, GD3, TRA-2-49, SSEA4, GD2, and CD141 to identify and isolate human otic progenitor cells through fluorescence-activated cell sorting (FACS) or other cell sorting techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If FGF3/10 induction method is used to generate otic progenitors, then otic progenitor cells can be produced, but the yield is inefficient (only approximately 20% of required cell types)
Solution Approach 1:
The patent applies preliminary action by performing FACS sorting at an early stage during otic differentiation (at day 7-14) to enrich otic progenitor cells before they fully differentiate into hair cells and neurons. This early enrichment ensures that the target cell population is captured while still present in sufficient numbers, avoiding the 20% loss that occurs when relying solely on terminal differentiation outcomes.
Solution Approach 2:
The patent replaces the inefficient biological selection mechanism (relying on natural differentiation to produce 20% otic progenitors) with a physical separation mechanism (FACS based on cell surface markers). This substitution allows for precise enrichment of otic progenitors regardless of their differentiation state, dramatically improving yield from the 20% baseline to much higher concentrations of target cells.
2Ease of operation
If FACS is used to separate cell populations, then cell isolation is possible, but specific cell-surface markers for human otic progenitors must be identified (which have not been previously identified)
Solution Approach 1:
The patent uses cell surface markers (such as SSEA-3, SSEA-4, TRA-2-49, and other glycolipid markers) as intermediary structures that enable FACS sorting of otic progenitors. These markers serve as detectable intermediaries that bridge the gap between the target cells and the FACS machinery, allowing physical separation without requiring direct manipulation or identification of the cells' functional properties.
Solution Approach 2:
The patent applies parameter changes by utilizing variations in cell surface marker expression patterns during otic differentiation. By monitoring changes in marker expression levels and combinations at different time points, the patent identifies optimal sorting parameters (specific marker combinations and expression thresholds) that maximize otic progenitor enrichment while minimizing contamination from other cell types.
3Reliability
If otic progenitors are derived from hESCs for clinical use, then therapeutic application is possible, but contamination with other cell types must be avoided
Solution Approach 1:
The patent performs preliminary FACS sorting during the differentiation process (at day 7-14) to enrich otic progenitors before they undergo extensive differentiation into multiple cell types. This timing is critical because it captures the progenitors while they are still relatively homogeneous and abundant, ensuring both high purity and sufficient cell numbers for therapeutic applications before the population becomes too heterogeneous.
Solution Approach 2:
The patent employs feedback by using multiple cell surface markers in combination for FACS sorting (e.g., SSEA-3+, SSEA-4+, TRA-2-49+ combinations). This multi-parameter sorting strategy provides feedback control over the enrichment process, allowing iterative optimization of sorting gates to achieve both high purity (>90% otic progenitors) and sufficient yield for clinical applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the precise identification and enrichment of human otic progenitor cells, improving their availability for cell therapy and drug screening applications, while minimizing contamination with non-otic progenitor cells.
Implementation Method 1
specific cell-surface markers have been identified that bind to the key cell-type e.g. otic progenitors
Implementation Method 2
An established method to separate out component cell populations from heterogeneous cultures is Fluorescence-Activated Cell Sorting (FACS)
Data Source
AI summary
The present invention relates generally to the identification and isolation of human otic progenitor cells. More specifically, the present invention relates to a method of using cell markers to identify and isolate human otic progenitor cells from a mixed population of cells, methods of enrichment and production of human otic progenitor cells, and associated kits for use in identification and/or isolation of human otic progenitor cells, wherein the cell markers are selected from SSEA1 (CD15), disialoganglioside GD3, TRA-2-49 (liver/bone/kidney alkaline phosphatase), SSEA4, ganglioside GD2 and CD141.